Tresiba and Lantus are both long-acting insulins used to manage blood sugar levels in people with type 1 or type 2 diabetes. (For more information on each’s drug uses, see the “What are Tresiba and ...

Dosage for Tresiba (insulin degludec) depends on the type of diabetes (type 1 or type 2) it is prescribed for and other factors. Your doctor may adjust your dosage over the course of your treatment.

PLAINSBORO, N.J., Sept. 25, 2015 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for ...

Tresiba (insulin degludec) is a brand-name drug that’s prescribed for diabetes. The medication is available as a liquid vial and a prefilled injection pen. The cost of Tresiba with and without ...

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...

Insulin degludec (Tresiba) is a long-acting insulin analogue given once daily as a subcutaneous injection for basal insulin therapy. It has a duration of action beyond 42 hours within the therapeutic ...

Bagsværd, Denmark, 21 January 2013 – Novo Nordisk today announced that the European Commission has granted marketing authorisations for Tresiba® (insulin degludec) and Ryzodeg® (insulin ...

ESOMAR-certified consulting firm Future Market Insights (FMI) projects the global smart insulin pens market is likely to surpass the billion dollar mark by 2021, expanding at a positive CAGR, as per a ...

People with diabetes have been hit with a five-month shortage of a vital medication. The Tresiba FlexTouch U100 insulin pen, which is manufactured by global pharmaceutical giant Novo Nordisk, is ...

ESOMAR-certified consulting firm Future Market Insights (FMI) projects the global smart insulin pens market is likely to surpass the billion dollar mark by 2021, expanding at a positive CAGR, as per a ...